| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 27/02/2025 | 16:43 | Business Wire | Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 25/02/2025 | 22:05 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 25/02/2025 | 15:26 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 06/02/2025 | 12:30 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 04/01/2025 | 00:12 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 03/01/2025 | 23:00 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 05/11/2024 | 14:31 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 28/10/2024 | 13:21 | Business Wire | PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 16/09/2024 | 13:15 | Business Wire | PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 27/06/2023 | 14:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 16/06/2023 | 22:46 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 10/05/2023 | 22:31 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 28/04/2023 | 22:08 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 03/04/2023 | 14:16 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 30/03/2023 | 12:09 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 27/03/2023 | 14:31 | Edgar (US Regulatory) | Amended Annual Report (10-k/a) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 17/03/2023 | 21:32 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 08/03/2023 | 23:32 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 09/01/2023 | 16:19 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 14/09/2022 | 12:15 | TipRanks | H.C. Wainwright Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 15/08/2022 | 15:10 | Edgar (US Regulatory) | Securities Registration Statement (s-1) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 10/08/2022 | 22:31 | Edgar (US Regulatory) | Small Company Offering and Sale of Securities Without Registration (d) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 05/08/2022 | 16:45 | TipRanks | H.C. Wainwright Sticks to Its Buy Rating for Nuvectis Pharma (NVCT) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 21/06/2022 | 15:56 | TipRanks | Nuvectis Pharma (NVCT) Receives a Buy from H.C. Wainwright | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 11/04/2022 | 18:25 | TipRanks | Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and Nuvectis Pharma (NVCT) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 05/04/2022 | 12:16 | TipRanks | H.C. Wainwright Keeps Their Buy Rating on Nuvectis Pharma (NVCT) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 28/03/2022 | 23:23 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 24/03/2022 | 18:16 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 24/03/2022 | 13:11 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:NVCT | Nuvectis Pharma Inc |
| 22/03/2022 | 15:55 | TipRanks | H.C. Wainwright Reiterates Their Buy Rating on Nuvectis Pharma (NVCT) | NASDAQ:NVCT | Nuvectis Pharma Inc |
